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this hypothesis in patients with Alzheimer’s disease (AD).
Methods: T2*-weighted MRI was performed in 16 AD patients and 15 control subjects. All mag-
netic resonance images were scored qualitatively by visual assessment, and quantitatively by measur-
ing phase shifts in the cortical gray matter and hippocampus. Statistical analysis was performed to
assess differences between groups.
Results: Patients with AD demonstrated an increased phase shift in the cortex in the temporoparietal,
frontal, and parietal regions (P , .005), and this was associated with individual Mini-Mental State
Examination scores (r 5 20.54, P , .05).
Conclusion: Increased cortical phase shift in AD patients demonstrated on 7-tesla T2*-weighted
MRI is a potential new biomarker for AD, which may reflect amyloid pathology in the early stages.
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Alzheimer’s disease (AD) can only be diagnosed with cer-
tainty at autopsy, based on the histological detection of senile
plaques containing fibrillary amyloid beta (Ab) and neurofi-
brillary tangles. Currently, because of the absence of vali-
dated sensitive and specific tests, the clinical diagnosis of
AD can only be made at a late stage of disease progression
and with a considerable degree of uncertainty—probable
AD, at best—and is based on criteria from the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition, and
the National Institute of Neurological, Communicative Dis-
orders and Stroke–Alzheimer’s Disease and Related Disor-
ders Association. Nevertheless, the histological hallmarks
of AD pathology, comprising amyloid plaques and neurofi-
brillary tangles, are known to occur up to 10 to 20 years beforethor. Tel.:131-71-5264376; Fax:131-71-5248256.
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itron emission tomography (PET) using Pittsburgh com-
pound B (PiB) has been introduced as a diagnostic tool to
detect cerebral amyloid in vivo [2–8]. The major
disadvantages of PiB-PET are the need to use a radioactive
tracer, the relative scarcity of institutions that can perform
such scans because of the requirement for an onsite cyclotron,
the inability to acquire anatomic and functional information
in the brain during the same examination, and the greater
chance of false positives, making interpretation of PiB-PET
scans more difficult, especially in the elderly, which hampers
the use of this method as a diagnostic tool in the elderly [9].
Earlier research demonstrated the potential of high-field
(7T) magnetic resonance imaging (MRI) in the diagnosis
of AD by showing distinct intensity changes in the cortex
on T2*-weighted images of postmortem brain specimens
of AD patients. These features included hypointense foci
and diffuse granular patterns of less distinct hypointense
foci in the cerebral cortex [10]. Similar patterns have beeneserved.
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human AD cases, and were attributed to the presence of
amyloid plaques using histological confirmation [11–19].
It has been proposed that the visualization on MRI of
plaques in humans and mice is based on the fact that these
deposits colocalize with iron, which gives rise to magnetic
susceptibility effects on T2*-weighted images over volumes
that are much larger than the actual size of amyloid plaques
[17,19–24]. An alternative method to measure these
susceptibility changes in the brain is to measure the
relative phase in regions of interest (ROIs), because it
has been shown that this is a reliable indicator of the iron
content in the brain [25–28]. Although previous studies
have demonstrated the potential of this approach in high-
field MRI [29,30], no clinical studies have been performed
yet on AD patients in vivo for the detection of AD pathology.
The overall aim of the current study is to confirm previous
postmortem findings by detecting AD pathology in the cere-
bral cortex and hippocampus using a novel, in vivo, 7T high-
field magnetic resonance (MR) approach.Fig. 1. Survey image on which the stack position of the two-dimensional
T2*-weighted gradient echo scan, including the frontal and parietal cortex
for amyloid detection, is shown. Image shows sagittal plane.2. Materials and methods
2.1. Participants
This study was approved by the local institutional review
board. In all cases, informed consent was obtained according
to the declaration of Helsinki [31]. In total, 16 AD patients
with a mean age of 76.9 years (range, 68–86 years;
10 male/6 female) and 15 control subjects with a mean age
of 75.1 years (range, 69–80 years; 10 male/5 female) were
included.
The AD patients were recruited from the memory clinic
of the Leiden University Medical Center. Memory clinic
patients were referred to the hospital by their general practi-
tioner or a medical specialist. Prior to the 7T study, these
patients all underwent a routine clinical protocol comprising
a whole-brain MRI (3T), a battery of neuropsychological
tests, and a general medical and neurological examination
performed by a neurologist, psychiatrist, or internist–geria-
trician. The diagnosis was made in a multidisciplinary con-
sensus meeting using the National Institute of Neurological,
Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association criteria for diagnosing
probable AD [32]. Participants with the diagnosis of pro-
bable AD who were capable of giving informed consent
(Mini-Mental State Examination (MMSE) score19 points)
with late-onset dementia (age .67 years) were selected for
inclusion in the 7T study either retrospectively within 1 year
after attending the memory clinic, or prospectively. Only
patients with a “pure” form of AD were selected. Patients
categorized as having a mixed form of dementia, or cerebral
amyloid angiopathy (CAA), were not included in the study.
Patients showing hemorrhagic lesions on T2*-weighted 3T
MRI and/or diagnosed as possible or probable CAA accord-
ing to the Boston criteria [33] were excluded.Healthy control subjects were recruited by focused adver-
tisement. Subjects with an age between 69 years and 80 years
who were living independently, had an MMSE score
25 points, and had a Geriatric Depression Scale score
4 points were selected for inclusion. Subjects were
screened by an internist–geriatrician (including for any
cognitive deficits), and subjects with the following diseases
were excluded: hemorrhagic and ischemic stroke, Morbus
Parkinson, dementia, mild cognitive impairment, diabetes
mellitus, rheumatoid arthritis, polymyalgia rheumatica,
cancer, heart failure, and chronic obstructive pulmonary
disease.2.2. MRI2.2.1. Image acquisition
MRI was performed on a whole-body human 7T MR
system (Philips Healthcare, Best, The Netherlands) using
a quadrature transmit and 16-channel receive head coil
(Nova Medical, Wilmington, MA). Participants were
scanned using a two-dimensional (2D), flow-compensated,
transverse T2*-weighted gradient echo scan that included
the frontal and parietal regions for amyloid detection with
a total imaging duration of 10 minutes. Positioning of this
stack was done on the sagittal plane of the survey within
the frontal and parietal region above the occipital lobe.
The middle of the stack was positioned through the corpus
callosum, just above the thalamus. Fig. 1 shows a typical
positioning of these 20 slices. Imaging parameters were rep-
etition time/echo time, 794/25 ms; flip angle, 45; slice
thickness, 1.0 mm with a 0.1-mm interslice gap; number
of slices, 20; field of view, 240! 180! 22 mm; and matrix
size, 1000! 1024; resulting in an in-plane nominal spatial
resolution of 0.24! 0.24mm2. The bandwidth per pixel was
46 Hz, corresponding to a readout length of approximately
22 ms. The frequency and phase-encoding directions were
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In addition, a coronal, 2D, flow-compensated T2*-weighted
gradient echo scan covering the hippocampus, with a total
imaging duration of 6 minutes, was performed. Positioning
of this stack was done on a T1-weighted image in sagittal
and coronal orientation. The stack was placed parallel to
and partly over the brainstem, and in front of it on the sagittal
T1-weighted image. Based on the T1-weighted images in the
coronal orientation, it was checked whether the stack in-
cluded the head of the hippocampus. Imaging parameters
were repetition time/echo time, 624/14 ms; flip angle, 40;
slice thickness, 3.0 mmwith no interslice gap; number of sli-
ces, 32; field of view, 240! 180! 96 mm; and matrix size,
480! 480; resulting in a nominal in-plane spatial resolution
of 0.5! 0.5 mm2. These sequences are very sensitive to im-
age artifacts arising from resonance frequency fluctuations
within the brain caused by slight patient movements, even
in areas significantly away from the head. A navigator
echo was included to correct for these artifacts [34]. Shim-
ming up to third order was performed using an image-
based shimming approach [35]. The phase images were
subsequently unwrapped by high-pass filtering with
a 92! 92 kernel size [36].
2.2.2. Image analysis
First, the T2*-weighted gradient echo images were eval-
uated, blinded for diagnosis, for hypointense foci by S. v. R.
and checked by M. v. B. as described in a previous ex vivo
study [10].
Image phase values in the cortex were determined using
the transverse 2D T2*-weighted gradient echo scans. Based
on the visual observation on unwrapped phase images of
a higher contrast between gray and white matter in AD pa-
tients than in control subjects, resulting from a higher signal
intensity within the gray matter, the phase values of the cor-
tical gray matter were determined in ROIs in four different
areas of the brain—temporoparietal left, temporoparietal
right, frontal, and parietal—which were positioned accord-
ing a detailed human brain atlas. Because of the laminar var-
iation in the cortical areas [29], histograms perpendicular to
the cortex within these regions were created to measure peak
gray matter phase values, over at least 10 cortical regions per
slice and per region. To correct for local macroscopic mag-
netic field inhomogeneities subcortical white matter phase
values were measured and used as an internal reference
value. Phase values for gray and white matter were measured
in these four areas per MRI slice for every other slice (10 in
total), resulting in 40 phase values for gray and white matter
separately per subject. Phase values of the different ROIs of
the four regions were averaged. Per subject, the overall
phase shift between cortical gray matter and subcortical
white matter (cortical phase shift) was calculated for each re-
gion and expressed in radians.
Phase values of the hippocampus were determined using
the coronal 2D T2*-weighted gradient echo scans. The hip-
pocampus was segmented manually, and phase values weredetermined on five consecutive slices, starting at the
head of the hippocampus, for the right and left hippocampus
separately. The slice showing the red nucleus most pro-
nounced was used as the middle slice for drawing an ROI,
and the two slices in front and after this slice were used to se-
lect the ROIs. For each subject, these fivemeasurements were
averaged for each hippocampus. Phase values of the white
matter were determined in three neighboring areas of subcor-
tical white matter on each of the five slices and averaged per
subject. The phase shift of the hippocampus was calculated
by the difference in phase value of the hippocampus and
white matter (hippocampal phase shift) and expressed in ra-
dians. Analysis of the hippocampus was performed only in
12 of the 16 AD patients and in 14 of the 15 control subjects
because of severe motion artifacts that could not be corrected
completely ( three subjects) or because participants were not
able to finish the whole scan protocol (two subjects).2.3. Statistics
A Mann–Whitney U test was used to assess differences
in age, gender, MMSE score, and phase measurements
between AD and control groups. Logistic regression anal-
ysis was used to assess the association between diagnosis
and intertissue phase shifts in the cortex and hippocampus,
corrected for age and gender. To assess the interaction
between cortical gray matter/hippocampal and white mat-
ter phase values, both were also entered as covariates in
one model. Receiver operating characteristic (ROC) anal-
ysis was performed to determine the area under the ROC
curve and to assess the optimal cutoff phase shift in the
cortex and hippocampus to detect AD with its correspond-
ing sensitivity, specificity, positive predictive value, and
negative predictive value. To determine the association be-
tween MMSE and phase shift in the cortex and hippocam-
pus, a linear regression analysis including a Pearson
correlation corrected for age and gender was performed.
All statistical analyses were performed with the Statistical
Package of Social Sciences (SPSS, version 17.0.1; SPSS,
Chicago, IL).3. Results
The characteristics of the participants are shown in
Table 1. No difference in age or gender was found between
patient and control groups. Scores for global cognitive func-
tioning (MMSE score) were significantly higher in control
subjects (29.0 points) than in patients with AD (22.5 points;
P , .001).
Fig. 2 shows representative, transverse T2*-weighted
magnitude and phase images of the parietal cortex of a sub-
ject with AD (Fig. 2A, B) and a control subject (Fig. 2C, D).
Fig. 3 shows coronal T2*-weighted magnitude and phase
images of the hippocampus of a subject with AD (Fig. 3A,
B) and a control subject (Fig. 3C, D). In none of the subjects
Table 1
Characteristics of AD patients and control subjects
Variables AD (n 5 16) Control (n5 15)
Mean age, years (range) 76.9 (68–86) 75.1 (69–80)
Male/female, n 10/6 10/5
Median MMSE score, points (range) 22.5 (19–26) 29.0 (27–30)
Abbreviations: AD, Alzheimer’s disease; MMSE, Mini-Mental State
Examination.
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or hippocampus.
Table 2 shows the mean phase shifts of the temporo-
parietal, frontal, parietal cortex, and the right and left hippo-
campus. For the temporoparietal, frontal, and parietal cortex,
a larger cortical phase shift (P , .005) was found in the AD
patients compared with control subjects (adjusted for age
and gender). For both hippocampi, no difference in phase
shifts between groups was observed. Analysis in which
both gray matter and white matter values were entered in
the logistic regression model showed that only the cortical
gray matter phase value, and not the white matter phase
value, was associated with diagnosis. For the hippocampus,
both gray and white matter phase values were not associated
with diagnosis.
To determine the diagnostic value of the phase measure-
ments in differentiating AD from control subjects,
ROC analysis was performed for each region. Table 3 shows
the area under the curve (AUC), cutoff value, sensitivity,Fig. 2. (A–D) Representative 0.24! 0.24-mm2 two-dimensional T2*-weighted g
a control subject (C and D). (A and C) Magnitude images. (B and D) Phase images
The phase images show that the contrast between gray and white matter is enhan
subject, indicating a larger cortical phase shift. Images show transverse planes.specificity, and positive and negative predictive values of
all regions selected. For the temporoparietal, frontal, and pa-
rietal cortex, an AUC between 0.79 and 0.85 was found, with
the regions all having a high specificity (90%–100%) and
a moderate to high sensitivity (50%–70%). Of these regions,
the parietal cortex demonstrated the highest AUC (0.85),
with a sensitivity of 69% and a specificity of 93%. The cor-
responding positive predictive value and negative predictive
value were 92% and 74%, respectively. Both hippocampi
demonstrated a lower AUC (right hippocampus, 0.66; left
hippocampus, 0.67), which resulted in a relatively lower
specificity and positive predictive value. The sensitivity
and negative predictive values were comparable with the re-
gions in the cortex.
There was a significant negative correlation (adjusted for
age and gender) between MMSE score and phase
shift in the left temporoparietal cortex (r 5 20.47,
[b 5 20.464, P , .05]), the right temporoparietal
cortex (r 5 20.41, [b 5 20.473, P , .05]), frontal cortex
(r 5 20.44, [b 5 20.404, P , .05]), and parietal cortex
(r 5 20.54, [b 5 20.501, P , .05]; all, P , .05). For the
right and the left hippocampus, there was no correlation be-
tween MMSE score and phase shift (right hippocampus,
r 5 20.25, P 5 .21 [b 5 20.168, P 5 .404], left hippo-
campus, r 5 20.27, P 5 .19 [b 5 20.190, P 5 .336]).4. Discussion
The first initial results of this study show that, using
a novel high-field imaging approach at 7T, patients withradient echo images show a patient with Alzheimer’s disease (A and B) and
of the parietal cortex. No hypointense foci are seen on the magnitude images.
ced in the patient with Alzheimer’s disease in comparison with the control
Fig. 3. (A–D) Representative 0.5! 0.5-mm2 two-dimensional T2*-weighted gradient echo images show a patient with Alzheimer’s disease (A and B) and
a control subject (C and D). (A and C) Magnitude images. (B and D) Phase images of the hippocampus. No hypointense foci are seen on the magnitude images.
The phase images show no difference between the patient with Alzheimer’s disease and the control subject in terms of image contrast between the hippocampus
and white matter.
Table 2
Mean phase shifts and standard deviations (SD) of the cortical and





(n 5 15) P value
Temporoparietal left 0.90 6 0.08 0.79 1 0.08 .001
Temporoparietal right 0.97 1 0.10 0.85 1 0.09 .001
Frontal 0.70 6 0.08 0.62 6 0.07 .004
Parietal 0.87 6 0.10 0.74 6 0.08 .000
Hippocampus right 0.09 6 0.04 0.07 6 0.03 .18
Hippocampus left 0.10 6 0.04 0.08 6 0.02 .14
Abbreviation: AD, Alzheimer’s disease; rad, radians.
NOTE: Boldface values denote statistical significance.
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phase shift on T2*-weighted images. These phase shifts be-
tween AD patients and control subjects have a high specific-
ity, independent of age and gender. Moreover, these phase
shifts correlated with individual MMSE scores. Of all corti-
cal areas studied, the parietal cortex shows the highest spec-
ificity combined with the highest sensitivity for the diagnosis
of AD and the strongest correlation with MMSE score. On
the other hand, phase shifts in the hippocampus were not sig-
nificantly increased in AD patients and did not correlate with
MMSE score.
High-field T2*-weighted MRI sequences are highly sen-
sitive for iron deposits in the brain [37]. In autopsy material
of AD patients, amyloid deposition and neurofibrillary tan-
gles as well as tau deficiency were found to colocalize
with neuronal iron accumulation [38–40]. Therefore, it is
likely that the increased cortical phase shift found on high-
field T2*-weighted MRI in patients with AD indirectly re-
flect AD pathology. Our data also show that the particular
distribution of the phase changes in the brain follows the
known cerebral distribution of amyloid deposition in AD.In our data, the neocortex—and more specifically, the parie-
tal lobes—allowed much better differentiating of AD pa-
tients from control subjects based on phase shift compared
with the hippocampus. In histological studies, it has been
demonstrated that the neocortex is the first structure in the
brain that is affected by amyloid depositions, whereas the
hippocampus is not only more mildly affected by amyloid
Table 3
Area under the curve (AUC), cutoff value, sensitivity, specificity, positive predictive value (PPV1), and negative predictive value (NPV2) of phase shifts in
differentiating between Alzheimer’s disease patients and control subjects for the different regions
Region AUC Cutoff value, rad Sensitivity, % Specificity, % PPV1, % NPV2, %
Temporoparietal, left 0.842 0.922 56 (9/16) 100 (15/15) 100 (9/9) 68 (15/22)
Temporoparietal, right 0.823 0.985 50 (8/16) 100 (15/15) 100 (8/8) 65 (15/23)
Frontal 0.794 0.690 56 (9/16) 93 (14/15) 90 (9/10) 67 (14/21)
Parietal 0.854 0.817 69 (11/16) 93 (14/15) 92 (11/12) 74 (14/19)
Hippocampus, right 0.655 0.074 75 (9/12) 71 (10/14) 69 (9/13) 77 (10/13)
Hippocampus, left 0.673 0.095 58 (7/12) 86 (12/14) 78 (7/9) 71 (12/17)
Abbreviation: rad, radians.
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neocortex [41–43]. This sequence of events has been
confirmed by PiB-PET studies showing high amyloid
loads in the parietal and frontal lobes and not in hippo-
campus [5–7,44,45]. However, phase shift changes might
be caused by other factors than iron-bound plaques, such
as iron itself or iron-bound CAA, but also by geometry
and orientation. Therefore, the absence of phase shift
changes in the hippocampus might, in part, be masked by
geometric distortions.
Phase measurement on T2*-weighted MRI at 7T has a
high specificity for AD compared with the reported specific-
ity of the methods that are currently considered state of the
art, such as cerebrospinal fluid (CSF) assay of the amyloid
peptide or PiB-PET imaging [9]. Previous studies indicated
that AD patients have reduced levels of Ab1–42 and increased
levels of t-tau and p-tau181p in CSF compared with control
subjects, in whom Ab1–42 is the most sensitive biomarker
for AD of CSF samples. 7T MRI had lower sensitivity
than these CSF analyses of Ab1–42 (69% vs 96%), but
had a higher specificity (93%–100% vs 77%) [46]. PET stud-
ies using PiB have shown the possibility of detecting cere-
bral amyloid accumulation, although the diagnostic utility
is limited [47], and numbers on sensitivity and specificity
are sparse. Mormino and colleagues [48] showed high sensi-
tivity (90%) and specificity (90%) in differentiating AD
patients from control subjects. However, within the group
of healthy subjects, the specificity drops with increasing
age, because the percentage of positive PiB-PET scans in-
creases rapidly, with 12% of the people in their 60s, 30%
in their 70s, and 50% in their 80s giving false-positive results
[45,49,50]. Our data show that measurement of phase
shift using T2*-weighted MRI might improve the specificity
of AD diagnosis.
Our study could not replicate the ex vivo finding of
hypointense foci, which might represent amyloid plaques
[10]. Although we corrected for resonance frequency varia-
tions, which are the main contributor to decreased image
quality in AD patients, with a navigator echo [34], it is
highly likely that even subvoxel degrees of motion blur the
hypointense foci.
A limitation of the current study is that phase measure-
ments might also be influenced by the geometry and orienta-tion of the scans [28]. We limited these effects as much as
possible by positioning every participant carefully in the
same manner. Moreover, phase values were measured in
the exact same way using a standardized method. Further-
more, we averaged multiple measurements of phase values
to cancel out the possible effects of geometry and orienta-
tion. A second limitation is that white matter phase values,
which were used to correct for magnetic field inhomogene-
ities, might have an influence on the results. However, our
data show that the observed phase changes were caused
mainly by phase shifts in the gray matter. A third limitation
is that we only included a relatively small number of AD pa-
tients and healthy control subjects, and therefore the sensi-
tivity and specificity in general cannot be determined
optimally, and the diagnostic accuracy in a group of memory
clinic patients is unclear. The specificity of the presented
method should be examined thoroughly by assessing differ-
ent categories of neurodegenerative diseases to evaluate the
ability to differentiate between different forms of dementia.
Moreover, the value of our method should be investigated in
the preclinical stages of AD. Therefore, in future studies we
aim to study cortical phase changes in patients with mild
cognitive impairment to evaluate the possibility of detecting
early AD pathology and to evaluate the use of these cortical
phase changes as an early treatment marker because the bi-
ological activity has already peaked before the symptomatic
stage [1]. In addition, future studies should address transla-
tional research from 7T to 3T MRI to investigate whether
our method could be used on 3T MRI data because 7T
MRI is not widely available. Still, we expect that 7T will
show larger phase shifts between AD patients and control
subjects than 3T, as a direct result of the higher field strength.
In conclusion, in this study we introduced a novel ap-
proach to detect cortical changes in AD patients, exploiting
the increased sensitivity of 7T MRI for iron in brain tissue.
Our current data demonstrate that cortical phase changes
are a potential new biomarker for AD.Acknowledgments
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1. Systematic review: We searched PubMed and ISI-
Web of Knowledge for articles including Alz-
heimer’s disease (AD), amyloid and AD pathology
detection, high-field magnetic resonance imaging
(MRI), phase measurements, cortical changes, bio-
markers for AD, and brain imaging. Our research
question evolved based on findings of our previous
postmortem study on AD brain specimens.
2. Interpretation: In this study, we introduced a novel
approach to detect cortical changes in AD patients
exploiting the increased sensitivity of 7T MRI for
iron in brain tissue. Our current data demonstrate
that cortical phase changes are a potential new bio-
marker for AD.
3. Future directions: The diagnostic value and ability
of our new approach as a biomarker for AD
should be investigated further by expanding the in-
clusion of the number of AD patients and control
subjects as well as include patients with mild cog-
nitive impairment (preclinical stage of AD) and
other dementias using 7T MRI and phase shift
measurements.References
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